PT2305656E - Isómeros óticos de um metabolito de iloperidona - Google Patents

Isómeros óticos de um metabolito de iloperidona

Info

Publication number
PT2305656E
PT2305656E PT100099159T PT10009915T PT2305656E PT 2305656 E PT2305656 E PT 2305656E PT 100099159 T PT100099159 T PT 100099159T PT 10009915 T PT10009915 T PT 10009915T PT 2305656 E PT2305656 E PT 2305656E
Authority
PT
Portugal
Prior art keywords
optical isomers
iloperidone metabolite
fouoro
isoxazol
piperidin
Prior art date
Application number
PT100099159T
Other languages
English (en)
Inventor
Hans O Kalkman
Dominique Grimler
Hequn Yin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2305656E publication Critical patent/PT2305656E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PT100099159T 2001-08-31 2002-08-30 Isómeros óticos de um metabolito de iloperidona PT2305656E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31639001P 2001-08-31 2001-08-31

Publications (1)

Publication Number Publication Date
PT2305656E true PT2305656E (pt) 2013-01-10

Family

ID=23228843

Family Applications (2)

Application Number Title Priority Date Filing Date
PT02767454T PT1425272E (pt) 2001-08-31 2002-08-30 Isómeros óticos de um metabolito de iloperidona
PT100099159T PT2305656E (pt) 2001-08-31 2002-08-30 Isómeros óticos de um metabolito de iloperidona

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT02767454T PT1425272E (pt) 2001-08-31 2002-08-30 Isómeros óticos de um metabolito de iloperidona

Country Status (10)

Country Link
US (4) US20050020632A1 (pt)
EP (2) EP2305656B1 (pt)
JP (6) JP2005504783A (pt)
AT (1) ATE518845T1 (pt)
CY (2) CY1112039T1 (pt)
DK (2) DK1425272T3 (pt)
ES (2) ES2398434T3 (pt)
HK (2) HK1066536A1 (pt)
PT (2) PT1425272E (pt)
WO (1) WO2003020707A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5067998B2 (ja) 2001-10-30 2012-11-07 ノバルティス アーゲー イロペリドンおよび星形ポリマーのデポー製剤
KR101020399B1 (ko) 2002-03-27 2011-03-08 글락소 그룹 리미티드 퀴놀린 유도체 및 5-ｈｔ6 리간드로서의 그의 용도
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
BRPI0412263B1 (pt) 2003-07-22 2019-10-15 Arena Pharmaceuticals, Inc. Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
CA3113166A1 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
US20070262395A1 (en) 2006-05-11 2007-11-15 Gibbons Jasper S Memory cell access devices and methods of making the same
US8008144B2 (en) 2006-05-11 2011-08-30 Micron Technology, Inc. Dual work function recessed access device and methods of forming
US20090306137A1 (en) * 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
WO2008121899A2 (en) 2007-03-29 2008-10-09 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
EP2152917B1 (en) 2007-05-18 2016-03-23 Vanda Pharmaceuticals Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
WO2009036100A2 (en) 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Prediction of qt prolongation based on snp genotype
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
PL2222300T3 (pl) 2007-12-13 2015-02-27 Vanda Pharmaceuticals Inc Sposób i skład preparatu do leczenia chorób z udziałem receptorów serotoniny
MX2010006520A (es) 2007-12-13 2010-11-30 Vanda Pharmaceuticals Inc Metodo y composicion para el tratamiento de una condicion mediada por alfa-adrenoceptor.
US20110061014A1 (en) 2008-02-01 2011-03-10 Energyhub Interfacing to resource consumption management devices
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US7824986B2 (en) 2008-11-05 2010-11-02 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
WO2010117941A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
US9074255B2 (en) 2009-04-06 2015-07-07 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to QT prolongation
EP2417267B1 (en) 2009-04-06 2016-08-17 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
JP5692872B2 (ja) 2009-04-06 2015-04-01 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｂａｉ遺伝子の配列又はその産物に基づいてｑｔ延長に対する素因を予測する方法
EP2515863A2 (en) 2009-12-23 2012-10-31 Lupin Limited Slow release pharmaceutical compositions of iloperidone
WO2012032532A1 (en) * 2010-09-07 2012-03-15 Symed Labs Limited "processes for the preparation of 4'-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3'-methoxyacetophenone and intermediates thereof"
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
AU2013232014B2 (en) * 2012-03-14 2016-06-16 Vanda Pharmaceuticals Inc. An iloperidone metabolite for use in the treatment of psychiatric disorders
ES2870498T3 (es) 2015-02-17 2021-10-27 Vanda Pharmaceuticals Inc Iloperidona para el tratamiento de esquizofrenia
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
WO2020172506A1 (en) * 2019-02-21 2020-08-27 Obi Pharma Inc. Methods of making high enantioselective secondary alcohols
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
WO2023201182A1 (en) 2022-04-13 2023-10-19 Vanda Pharmaceuticals Inc. Treatment of parkinson's disease and parkinson's disease psychosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
EP0402644B1 (en) * 1989-05-19 1995-08-16 Hoechst-Roussel Pharmaceuticals Incorporated N-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines,a process for their preparation and their use as medicaments
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
JPH05286868A (ja) 1992-04-03 1993-11-02 Kiyoshi Okawa 制がん剤複合体およびそのスクリーニング法
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
EP0997458A4 (en) * 1997-07-03 2003-03-05 Asahi Chemical Ind NOVEL TRICYCLIC COMPOUNDS HAVING SATUROUS CORES AND MEDICINAL COMPOSITIONS CONTAINING THEM
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS

Also Published As

Publication number Publication date
EP1425272B1 (en) 2011-08-03
EP2305656A1 (en) 2011-04-06
WO2003020707A1 (en) 2003-03-13
ATE518845T1 (de) 2011-08-15
JP2015214577A (ja) 2015-12-03
JP2013227335A (ja) 2013-11-07
US20110201646A1 (en) 2011-08-18
ES2370634T3 (es) 2011-12-21
HK1066536A1 (en) 2005-03-24
US20130296366A1 (en) 2013-11-07
JP2010100633A (ja) 2010-05-06
ES2398434T8 (es) 2017-10-09
EP1425272A1 (en) 2004-06-09
CY1112039T1 (el) 2015-11-04
ES2398434T3 (es) 2013-03-19
US20050020632A1 (en) 2005-01-27
US20090176739A1 (en) 2009-07-09
US7977356B2 (en) 2011-07-12
JP2015227368A (ja) 2015-12-17
CY1113550T1 (el) 2016-06-22
JP2005504783A (ja) 2005-02-17
HK1156309A1 (en) 2012-09-07
JP2013116905A (ja) 2013-06-13
US8314129B2 (en) 2012-11-20
EP2305656B1 (en) 2012-10-24
DK2305656T3 (da) 2013-02-11
PT1425272E (pt) 2011-10-19
DK1425272T3 (da) 2011-11-21

Similar Documents

Publication Publication Date Title
HK1156309A1 (en) Optical isomers of an iloperidone metabolite
RS50624B (sr) Monohidrohloridna so 1-[3-[3-(4-hlorofenil)propoksi]propil]piperidina
NO2015002I2 (no) Ataluren (3-[5-(2-fluorfenyl)-[ 1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav
NO20051965D0 (no) Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
NO20071193L (no) Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
PL1651040T3 (pl) Grzybobójcze trójskładnikowe kompozycje substancji czynnych
NO20050429L (no) Substituert kinolin-CCR5-reseptorantagonister
JP2005504783A5 (pt)
NO20033732D0 (no) N-substituerte nonaryl-heterosykliske NMDA/NR2B-antagonister
NO20062370L (no) Amidderivater
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
JP2010519243A5 (pt)
NZ594765A (en) Anthelmintic agents and their use
RS54608B1 (en) CGRP RECEPTOR ANTAGONITY
ATE347550T1 (de) Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure
HK1070363A1 (en) Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serineprotease factor xa
ZA200707888B (en) Process for the preparation of indolone derivative
DE602004009079D1 (de) Carbostyril-derivative zur beschleunigten speichelabsonderung
DE50005937D1 (de) 3-(4,5-dihydroisoxazol-5-yl)benzoylpyrazole
PL353977A1 (en) Method of obtaining 4-[1-hydroxy-4-[4-(hydroxydiphenyldimethyl)-1-piperidinylbutyl]-alpha,alpha-dimethylbenzene acetic acid
DE60013751D1 (de) Optisch aktive 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone als selektive 5-HT1D Rezeptor Antagonisten
SE0102809D0 (sv) Novel compounds
HN2005000205A (es) Compuestos terapeuticos
RU2001103738A (ru) Применение производных тетрагидропиридин (или 4-гидроксипиперидин) бутилазолов при получении лечебного средства для лечения боли